Q3 2024 Bionano Genomics Inc Earnings Call Transcript

Nov 13, 2024 / 09:30 PM GMT

Release Date Price: €315.84

Transcript 10-Q8-K

Key Points

Positve

Bionano Genomics Inc (BNGO) has significantly reduced operating expenses and cash burn, achieving a 69% decrease in GAAP operating expenses and a 49% decrease in non-GAAP operating expenses compared to the previous year.
The company reported a 27% increase in flow cell sales year-over-year, indicating growing utilization among existing customers.
Bionano Genomics Inc (BNGO) has successfully implemented a new go-to-market strategy focusing on high-volume routine users, which is expected to drive future growth in consumables.
The company has made progress in reimbursement initiatives, with a new CPT code established for optical genome mapping, potentially increasing adoption and utilization.
There is strong demand for the new Stratus system, particularly in key geographies like Europe, the US, Canada, and Israel, which addresses higher throughput needs for customers.

Negative

Bionano Genomics Inc (BNGO) experienced a 35% year-over-year decrease in revenue for Q3 2024, partly due to the discontinuation of clinical services products.
The company's GAAP gross margin was negative 139% due to one-time charges related to inventory write-downs and discontinued services.
The transition to a new operating strategy has resulted in slower growth in the optical genome mapping installed base, with only five net placements in Q3 2024.
There are potential additional write-downs of receivables related to discontinued clinical services, which could impact future financial results.
Delays in system purchases have affected revenue, and while these processes are ongoing, there is uncertainty about the timing of their completion.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BNGO.OQ - Bionano Genomics Inc
Q3 2024 Bionano Genomics Inc Earnings Call
Nov 13, 2024 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and welcome to the Bio Nana third quarter, 2024 earnings conference call. Today's conference is being recorded at this time. I would like to turn the conference over to David Holmes from investor relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator and good afternoon, everyone.

Welcome to the Bionano third quarter, 2024 financial results conference call leading the call today is Dr Eric Holman CEO and Principal Financial Officer of Bionano and he is joined by Mark Adam Check. Bionano's Vice President of Accounting and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.